PARI collaborates with pharmaceutical companies to develop and commercialise advanced aerosol therapies. These are based on the optimisation of an efficient aerosol delivery platform, called eFlow Technology, to a drug formulation. Such eFlow Technology nebulisers are tailored to specific medications and the needs of the respective patient population.
PARI has extensive experience in the field of liquid aerosol delivery to the respiratory tract. More than 15 pharmaceutical companies already trust in eFlow Technology nebulisers and PARI´s expertise for the administration of their inhaled medication - from preclinical to commercial. Patients benefit from short nebulisation times, ease-of-use and clinically proven aerosol delivery.
Find out more about our technology, projects, services and success stories!